Cadre (CDRE) Q1 2026 Earnings Call Transcript

Cadre Holdings reported Q1 net sales of $155.4 million, up 19% year over year, and ended the quarter with a record $355 million backlog, while reaffirming full-year guidance for $736 million-$758 million in revenue and $136 million-$141 million in adjusted EBITDA. The company also completed two acquisitions, TIER Tactical and Alien Gear Holsters, and said net leverage is below 3x, with the May dividend marking the 17th consecutive payment since the IPO. Management flagged some softness in discretionary distribution demand, but highlighted strong nuclear and defense-related tailwinds from the DOE budget shift and expects most backlog to convert within 2026.

Analysis

CDRE is turning backlog into a near-term earnings accelerant, but the more important point is that mix is finally becoming an explicit margin lever rather than a vague “growth” story. The large European blast-attenuation win and the shift toward defense-linked nuclear spend both push revenue into higher-visibility, higher-barrier channels where pricing discipline is stronger and customer retention is longer. That means the stock’s real re-rating catalyst is not Q1 growth itself; it is the market gaining confidence that the back half can inflect margins while leverage trends toward the low-2x area without starving M&A.

The softer company-owned distribution commentary is the only signal that should make us pause, but it is also the least threatening part of the business. If that weakness stays confined to discretionary third-party products, it may actually improve reported mix because the CADRE-made safety SKUs appear resilient; in other words, a cleaner portfolio can look slower on top-line but better on quality of earnings. The key second-order effect is competitive: smaller distributors and marginally differentiated consumer brands are the most exposed if procurement budgets tighten, while CADRE’s mission-critical positioning should let it keep share even in a slower municipal environment.

The contrarian risk is that the market may be overestimating how fast the new backlog converts, especially given the 2027-shipping profile of the largest seat contract and the fact that one acquisition is still a bankruptcy-recovery story with uncertain normalization. If defense/nuclear budget politics slip, or if local law-enforcement budgets compress harder than management is modeling, the stock could go from “guidance confidence” to “execution prove-it” quickly. The timeline matters: this is a months-ahead earnings/margin story, not a days-ahead catalyst, so any miss in Q2 conversion or back-half margin ramp would likely hit the multiple before it hits the P&L.

Key Decisions for Investors

• Go long CDRE on pullbacks over the next 1-2 weeks; the setup favors a 6-12 month rerate if back-half margin expansion comes through, with downside protected by sub-3x leverage and dividend support.
• Pair trade: long CDRE / short a basket of lower-quality industrial distributors or consumer safety retailers for 3-6 months, targeting portfolio simplification and mission-critical end-market resilience as the spread driver.
• Buy CDRE Jan-2027 calls or call spreads if implied volatility is reasonable; the 2027 defense/nuclear budget shift creates a longer-dated upside path that the market may not be fully pricing yet.
• Trim/add rule: if Q2 shows distribution softness spreading into CADRE-made products, reduce exposure immediately; that would be the earliest signal that the “discretionary-only” thesis is breaking.
• Watch for an entry to add after any post-earnings dip caused by concern over the 2027-shipping contract; that should be viewed as timing noise unless management also lowers full-year organic growth or margin guidance.